Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLNN
CLNN logo

CLNN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Clene Inc (CLNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.350
1 Day change
-4.87%
52 Week Range
13.500
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Clene Inc (CLNN) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The lack of significant positive catalysts, weak financial performance, and absence of strong trading signals suggest that holding off on this stock is prudent for now.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 73.347, and moving averages are converging, showing no clear trend. Key resistance levels are at 6.458 and 7.009, while support levels are at 4.674 and 4.123.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • Gross margin increased by 26.09% YoY, indicating improved operational efficiency.

Neutral/Negative Catalysts

  • Revenue dropped significantly by -82.76% YoY in Q3 2025, and EPS declined by -30.33% YoY. Net income remains negative at -$8.78M despite a slight improvement. No recent news, analyst updates, or significant trading trends from hedge funds or insiders.

Financial Performance

In Q3 2025, revenue dropped to $15,000 (-82.76% YoY), net income improved slightly to -$8.78M (+9.90% YoY), EPS decreased to -0.85 (-30.33% YoY), and gross margin increased to 100 (+26.09% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target updates available.

Wall Street analysts forecast CLNN stock price to rise
5 Analyst Rating
Wall Street analysts forecast CLNN stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.675
sliders
Low
30
Averages
30.4
High
31
Current: 6.675
sliders
Low
30
Averages
30.4
High
31
Maxim
Naz Rahman
Buy
maintain
$20 -> $30
AI Analysis
2025-12-03
Reason
Maxim
Naz Rahman
Price Target
$20 -> $30
AI Analysis
2025-12-03
maintain
Buy
Reason
Maxim analyst Naz Rahman raised the firm's price target on Clene to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light, NfL, and glial fibrillary acidic protein, GFAP, which "clears way" for an NDA filing, the analyst says.
Benchmark
Buy
downgrade
$33 -> $31
2025-09-10
Reason
Benchmark
Price Target
$33 -> $31
2025-09-10
downgrade
Buy
Reason
Benchmark lowered the firm's price target on Clene to $31 from $33 and keeps a Buy rating on the shares. Having obtained agreement from the FDA regarding the statistical analysis plan, Clene continues to work toward an anticipated NDA submission in Q4 for CNM-Au-8 in the treatment of ALS, the analyst noted while updating the firm's model.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLNN
Unlock Now

People Also Watch